Arranta Bio to expand manufacturing to include mRNA vaccine support

By The Science Advisory Board staff writers

September 24, 2021 -- Arranta Bio, a contract development and manufacturing organization, plans to expand its manufacturing capacity at its Watertown, MA, facility to include support for developers of mRNA vaccines.

The expanded capacity will allow the company to support infectious disease and therapeutic vaccine developers through the manufacture of raw materials, in vitro transcription, mRNA purification, and lipid nanoparticle formulation, it said.

Arranta Bio adds new manufacturing facility
Arranta Bio is adding a 130,000-sq-ft facility in Boxborough, MA, to complement its facilities in Watertown, MA, and Gainesville, FL, bringing its total...

Copyright © 2021

Interphex 2021
October 19-21
New York City, New York United States
Building Biology in 3D Hybrid Symposium
October 26-27
La Jolla, California United States
Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter